Drug Type Small molecule drug |
Synonyms CDP 323, CDP323 |
Target |
Mechanism VCAM1 inhibitors(Vascular cell adhesion molecule 1 inhibitors), α4β1 antagonists(Integrin alpha-4/beta-1 antagonists), α4β7 antagonists(Integrin alpha-4/beta-7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H29BrN4O3 |
InChIKeyQCYAXXZCQKMTMO-QFIPXVFZSA-N |
CAS Registry455264-30-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | Phase 2 | GB | 01 Jul 2008 | |
Multiple Sclerosis | Phase 2 | US | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | BE | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | CA | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | FI | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | FR | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | DE | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | HU | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | NL | 01 May 2007 | |
Multiple Sclerosis | Phase 2 | ES | 01 May 2007 |